Ferring Bravelle in vitro use
This article was originally published in Pharmaceutical Approvals Monthly
Ferring's Bravelle (urofollitropin) is approved for use in in vitro fertilization Dec. 19. The human-derived follicle-stimulating hormone was shown to similar efficacy to genetically engineered FSH in two trials of patients undergoing controlled ovarian hyperstimulation for IVF. The studies found comparable pregnancy outcomes for Bravelle and Follistim (recombinant follitropin beta), with significantly less injection site pain, Ferring said. Bravelle was approved May 6, 2002, for ovulation induction following pituitary suppression (Pharmaceutical Approvals Monthly, June 1, 2002, In Brief). Ferring is also touting Bravelle as the lowest priced product in its categor
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.